- Home
- IMMP vs APAD Comparison
IMMP vs APAD Comparison
Compare IMMP & APAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- APAD
- Stock Information
- Founded
- IMMP 1987
- APAD 2022
- Country
- IMMP Australia
- APAD Hong Kong
- Employees
- IMMP N/A
- APAD N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- APAD
- Sector
- IMMP Health Care
- APAD
- Exchange
- IMMP Nasdaq
- APAD Nasdaq
- Market Cap
- IMMP 256.1M
- APAD 280.7M
- IPO Year
- IMMP N/A
- APAD 2025
- Fundamental
- Price
- IMMP $1.90
- APAD $10.09
- Analyst Decision
- IMMP Buy
- APAD
- Analyst Count
- IMMP 1
- APAD 0
- Target Price
- IMMP $7.00
- APAD N/A
- AVG Volume (30 Days)
- IMMP 128.2K
- APAD 82.7K
- Earning Date
- IMMP 02-22-2026
- APAD 01-01-0001
- Dividend Yield
- IMMP N/A
- APAD N/A
- EPS Growth
- IMMP N/A
- APAD N/A
- EPS
- IMMP N/A
- APAD 0.14
- Revenue
- IMMP $3,306,742.00
- APAD N/A
- Revenue This Year
- IMMP N/A
- APAD N/A
- Revenue Next Year
- IMMP N/A
- APAD N/A
- P/E Ratio
- IMMP N/A
- APAD $72.28
- Revenue Growth
- IMMP 31.28
- APAD N/A
- 52 Week Low
- IMMP $1.32
- APAD $9.87
- 52 Week High
- IMMP $2.71
- APAD $10.21
- Technical
- Relative Strength Index (RSI)
- IMMP 56.87
- APAD N/A
- Support Level
- IMMP $1.68
- APAD N/A
- Resistance Level
- IMMP $1.95
- APAD N/A
- Average True Range (ATR)
- IMMP 0.09
- APAD 0.00
- MACD
- IMMP 0.01
- APAD 0.00
- Stochastic Oscillator
- IMMP 82.14
- APAD 0.00
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
About APAD A Paradise Acquisition Corp. Class A Ordinary Shares
A Paradise Acquisition Corp is a blank check company.